LONDON--(BUSINESS WIRE)--Technavio’s latest report on the global neurological biomarkers market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
Biomarkers are the indicators considered for identifying specific diseases. They are mainly used for identification of the progress of a particular disease and evaluation of an effective method for drug target identification. The biomarkers specifically involved in the identification of the neurological disorders are called neurological biomarkers.
Srinivas Sashidhar, a lead analyst from Technavio, specializing in research on medical devices sector, says, “The global neurological biomarkers market is expected to grow at a high rate during the forecast period. The market is being driven by the increase in older population, increased cases of various neurological disorders, and increasing initiatives from governments to support the research and development of neurological biomarkers.”
Neurological biomarkers will play a crucial role in advanced characterization of neuropathologies and help in selection of appropriate treatment strategies. Personalized medicine will change the paradigm integrating large-scale molecular and clinical information.
Request a sample report: http://www.technavio.com/request-a-sample?report=52871
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three emerging trends driving the global neurological biomarkers market according to Technavio healthcare and life sciences research analysts are:
- Integrated biology approach will be the key focus area
- Development of novel radiotracers
- Evolution of miRNA
Integrated biology approach will be the key focus area
Single-cell biosensors have already been developed for protein and DNA biomarkers. The development of nanosensors, which can be used for neuro-based analytes, is expected to emerge. For example, BRAF tests for neuropathology is under research. Software like Genedata Expressionist that can integrate and analyze data from different omics platforms and deliver meaningful clinical biomarkers will be the next focus. Systems Biology approaches will enter into routine use for biomarker validation, pre-clinical drug development, and clinical trials (virtual patients) in the next 4-5 years. “Multi-marker blood-based tests that can diagnose and differentiate between closely related neurodegenerative disorders will be a critical emerging area,” says Srinivas.
Development of novel radiotracers
The development of novel radiotracers for neuro biomarkers that aid diagnostic and clinical applications for diseases. PET is an atomic imaging procedure that permits in-vivo estimations of important physiological parameters, for example, glucose metabolism and neuroreceptor binding, enabling in-depth understanding and analysis of the pathophysiology of neurological diseases such as Alzheimer's disease (AD).
PET imaging is an effective tool to examine the numerous features of Parkinson's disease (PD) in-vivo. The technique has expanded understanding encompassing the differential diagnostic study of PD, the progression of the disease condition, complications emerging from drugs, and the non-motor indications of the disease. Besides, PET imaging will permit more prominent progression of alternative approaches to treatment therapy in PD as it can be utilized to assess the viability of a treatment and screen changes longitudinally.
Evolution of miRNA
MicroRNAs belong to a class of small RNAs that are derived from polymerase II controlled transcriptional regions. Apart from inclusion in wide options of biological procedures, miRNAs were earlier detected for their potential in disease diagnostics and therapeutics. Because of miRNAs stable feature, they could be utilized as biomarkers. The miRNAs have stability in paraffin-embedded tissue samples or human plasma and are used to determine the state of neurological diseases.
Creating miRNA therapeutics for neurological diseases is a promising opportunity but extremely challenging. The promise comes from the size of miRNAs being very small, which makes them agreeable for control using short synthetic oligonucleotides or engineered viruses. Likewise, the way that each miRNA directs various target transcripts of the same pathway predicts that such manipulations may influence a whole pathway as opposed to a single gene. This offers that low-dose drug targeting the top miRNA in such a hierarchic pyramid would be adequate to affect the change in a whole pyramid.
However, these same elements, which make miRNAs such encouraging agents for therapeutic modifications, present significant challenges. The plenty of opportunities for each miRNA, in particular, cell sorts, are yet a long way from being illustrated, which suggests that the objectives to be influenced may not be those wanted to be controlled. Besides, the miRNA direction of cholinergic signaling includes the above-mentioned components of complexity and hierarchy applicable to various neuropathologies and neurodegenerative disorders.
Browse Related Reports:
- Global Biobanking Market 2016-2020
- Global Central Nervous System Disorders Therapeutics Market 2016-2020
- Global Neurophysiology Needles and Electrodes Market 2016-2020
Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact enquiry@technavio.com with your requirements and our analysts will be happy to create a customized report just for you.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
